Blood Biomarkers for Screening of Alzheimer's Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50+
SponsorPeking University First Hospital
About this trial
The goal of this observational study is to estimate the screen performance of blood biomarkers of interest (Aβ40 and Aβ42, P-Tau181, P-Tau217, GFAP and NfL) in patients with Alzheimer's disease (AD), mild cognitive impairment due to AD, and cognitively normal individuals. The main questions it aims to answer are:
* to identify core blood biomarker suitable for early screening of AD. * to establish a comprehensive model for the early identification of AD.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age ≥ 50 years;
AD (meets the 2011 NIA-AA AD diagnostic criteria), or MCI (meets the 2004 Peterson MCI diagnostic criteria), or cognitively normal subjects;
Signed informed consent form.
Disqualifiers
The presence of other disorders that can cause cognitive impairment;
Unable to cooperate with the completion of cognitive assessment;
Refusal to draw blood.
Trial population
Alzheimer's disease, mild cognitive impairment due to AD, and cognitively normal individuals.
Trial design
Design model
Cohort
Time perspective
Cross-sectional
Treatments tested in this trial
Blood biomarker
Diagnostic testBlood biomarker
Treatment groups
180 Participants
are divided into 1 treatment groupGroup A: different stages of individuals with Alzheimer's disease1 intervention
Trial outcomes
Primary outcomes
1
Evaluate the diagnostic accuracy of blood biomarkers of Aβ42, Aβ40, Aβ42/Aβ40, P-Tau181, P-Tau217, GFAP and NfL.
Time frame
2 yearsSecondary outcomes
1
Evaluate the diagnostic accuracy of a comprehensive model combined with core blood biomarkers and clinical information.
Time frame
2 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov